The Insight Partners published latest research report on “Drug Delivery Market Growth Report, Size, Share, Trends & Growth Forecast to 2028 - COVID-19 Impact and Global Analysis By Route of Administration, Distribution Channel and End User”, the global market size is expected to grow from USD 20,99,856.7 million in 2022 to USD 32,54,594.2 million by 2028; it is estimated to record a CAGR of 7.7% from 2023 to 2028.
The Insight Partners published latest research report on “Drug Delivery Market Growth Report, Size, Share, Trends & Growth Forecast to 2028 - COVID-19 Impact and Global Analysis By Route of Administration, Distribution Channel and End User”, the global market size is expected to grow from USD 20,99,856.7 million in 2022 to USD 32,54,594.2 million by 2028; it is estimated to record a CAGR of 7.7% from 2023 to 2028.
Request Sample PDF Brochure: https://www.theinsightpartners.com/sample/TIPRE00029924
Global Drug Delivery Market: Competitive Landscape and Key Developments:
Pfizer Inc, Johnson & Johnson, Becton Dickinson and Co, Novo Nordisk AS, Boston Scientific Corp, Baxter International Inc, Gerresheimer AG, Kindeva Drug Delivery LP, GlaxoSmithKline Plc, Bausch Health Companies, Novartis AG, Sever Pharma Solutions, and Boehringer Ingelheim International are a few of the key companies operating in the drug delivery market. These companies adopt product innovation strategies to meet evolving customer demands, which allows them to maintain their brand name. A few of the recent developments in the global drug delivery market are mentioned below:
In April 2023, Baxter International Inc. announced the U.S. launch of ZOSYN (piperacillin and tazobactam) Injection. Zosyn premix is indicated for treating multiple infections caused by susceptible bacteria and is available in Baxter’s proprietary single-dose Galaxy containers. Baxter sells Zosyn premix in 2.25 g in 50 mL, 3.375 g in 50 mL, and 4.5 g in 100 mL presentations.
In October 2022, The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. FDA had approved TECVAYLI (teclistamab-cqyv) for treating adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy. TECVAYLI is a first-in-class, bispecific T-cell engager antibody administered as a subcutaneous treatment. TECVAYLI is Janssen’s fourth approved treatment for multiple myeloma, which further diversifies the company’s industry-leading oncology portfolio.
In June 2022, Novartis acquired Kedalion Therapeutics and its AcuStream technology, an innovative device having the potential to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye. The acquisition enhanced the Novartis ophthalmic portfolio, advancing efforts to investigate transformative ophthalmic methods to address unmet patient needs in front-of-eye conditions.
Directly Purchase Premium Copy of Drug Delivery Market Growth Report (2023-2028) at: https://www.theinsightpartners.com/buy/TIPRE00029924
Drug delivery are various methodologies used to inject drugs or chemicals into the body. Some of the drug delivery available in the market include transmucosal, oral, injectable, topical, implantable, and ocular, among others. Drug delivery is the technology primarily used for the controlled or targeted delivery of various therapeutic agents to treat various diseases or improve the patient’s health.
Global Drug Delivery Market Share Report, Segmentations, Regional & Country Scope:
| Report Coverage | Details |
| Market Size Value in | USD 20,99,856.7 million in 2022 |
| Market Size Value by | USD 32,54,594.2 million by 2028 |
| Growth rate | CAGR of 7.7% from 2023 to 2028 |
| Forecast Period | 2023-2028 |
| Base Year | 2022 |
| No. of Pages | 314 |
| No. of Tables | 219 |
| No. of Charts & Figures | 93 |
| Historical data available | Yes |
| Segments covered | Route of Administration, Distribution Channel, and End User |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Country scope | US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina |
| Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Companies Covered | Becton, Dickinson and Co, Novo Nordisk AS, Boston Scientific Corp, Baxter International Inc, Gerresheimer AG, Kindeva Drug Delivery LP, GlaxoSmithKline Plc, Bausch Health Companies, Novartis AG, Boehringer Ingelheim International, Sever Pharma Solutions, Pfizer Inc., Johnson & Johnson. |
Browse key market insights spread across 314 pages with 219 list of tables & 93 list of figures from the report, “Drug Delivery Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Route of Administration (Injectable Drug Delivery, Oral Drug Delivery, Transmucosal Drug Delivery, Topical Drug Delivery, Implantable Drug Delivery, and Ocular Drug Delivery), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and End User (Hospitals and Clinics, Home Care Settings, and Other End User)” in detail along with the table of contents: https://www.theinsightpartners.com/reports/drug-delivery-market
Rising Incidence of Chronic Diseases to Fuel Global Drug Delivery Market Growth during Forecast Period:
According to the Centers for Disease Control and Prevention (CDC), ~6 in 10 people in the US suffered from at least one chronic disease, while ~4 in 10 people had two or more chronic diseases as of 2019. Many chronic medical conditions worsen with time, resulting in an enormous burden on patients’ families and society. According to the projections of the American Cancer Society (ACS), the US is likely to record ~1,958,310 new cancer cases and 609,820 deaths in 2023. Diabetes is a life-threatening chronic disease with no specialized cure. All types of diabetes can lead to various complications in different body parts and increase the risk of premature death. Heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage are the major complications associated with this disease. Cases of diabetes have been increasing significantly across the world. According to the International Diabetes Federation (IDF), ~425 million people worldwide were living with diabetes in 2017, and the number is further expected to reach 629 million by 2045.
The increased prevalence of chronic diseases has promoted more intensive research and development (R&D) in drug delivery systems in the past few decades. The therapeutic efficacy of drugs used to treat chronic disease can be improved with optimal drug delivery systems, such as nanoparticles (e.g., ceramic, polymeric, and metallic), micelles, liposomes, and dendrimers. Administration of a drug with a drug delivery system can also help reduce systemic side effects of drugs. Various drug delivery vehicles have been introduced for a targeted and controlled delivery of therapeutics against a wide range of chronic diseases, such as diabetes, cancer, atherosclerosis, myocardial ischemia, asthma, pulmonary tuberculosis, Parkinson’s, and Alzheimer’s. An appropriate drug delivery system enhances the therapeutic efficacy of any drug by ensuring high drug bioavailability for a long duration. Targeted drug delivery systems (TDDS) release drugs in a controlled manner at a preselected site in a subject’s body. Nanotechnology-based delivery systems are making a significant impact on cancer treatment, and polymers play a key role in the development of these nanoparticulate carriers. In addition to the versatility of the administration route, a few of the noteworthy technological advantages of nanotherapeutic drug delivery systems (NDDS) are prolonged half-life, improved biodistribution, increased drug circulation time, controlled and sustained drug release, and elevated intercellular drug concentration.
Speak to Analyst at https://www.theinsightpartners.com/speak-to-analyst/TIPRE00029924
Given the chronic nature of these conditions, patients with chronic diseases rely on continuous drug treatment, which is associated with an ongoing risk of side effects. Developing appropriate delivery systems for targeted drugs can promote the accumulation of targeted medicines in pathogenic lesions, reduce systemic side effects, and improve patient outcomes. Thus, the increasing incidences of chronic and lifestyle diseases bolster the growth of the drug delivery market.
Go through further research published by The Insight Partners: (Purchase with 10% Instant Discount):
Drug Delivery Systems Market to 2027- Global Analysis and Forecasts
Nasal Drug Delivery Systems Market Forecast to 2028 - Covid-19 Impact and Global Analysis
Liposome Drug Delivery Market Forecast to 2027 - COVID-19 Impact and Global Analysis
Transdermal Drug Delivery System Market Forecast to 2027 - COVID-19 Impact and Global Analysis
Oral Drug Delivery Market Forecast to 2028 - Covid-19 Impact and Global Analysis
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876
Press Release: https://www.theinsightpartners.com/pr/drug-delivery-market